PATJ

Across TCGA pan-cancer cohorts, PATJ mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PATJ data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PATJ mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PATJ expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

HNSC, COAD, and LSCC are the cancer types where PATJ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	1.000	0.344	.009	24	view →
COAD	DFS	Median	II,III,IV	1.000	0.932	.040	12	view →
LSCC	DFS	Tertile	II,III,IV	0.929	0.654	.012	5	view →
LUAD	DFS	Median	All	0.486	0.728	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PATJ–HNSC (OS)

Open the HNSC breakdown →